What's New | Decker

Over the past two decades, considerable progress has been made in the medical management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Recently the field has seen the addition of several new pulmonary vasodilator agents: a soluble guanylate cyclase stimulator (riociguat), a new endothelin receptor antagonist (macitentan) and two new oral prostanoid agents (treprostinil and selexipag).
Initial combination therapy for the treatment of pulmonary arterial hypertension has heralded a new era in the treatment of PAH. Patients receiving initial combination therapy with a phosphodiesterase inhibitor, tadalafil and an endothelin receptor antagonist, ambrisentan demonstrated improved progression-free survival compared with monotherapy with either tadalafil or ambrisentan.
For patients with inoperable or persistent chronic thromboembolic pulmonary hypertension, riociguat has emerged as an attractive alternative.

Use of angioembolization for diagnosis and treatment of hemorrhage; improvement in angioembolization devices and technology
Success of thoracic endovascular aortic repair (TEVAR) using endovascular stent grafts to improve morbidity and mortality among patients who survive blunt thoracic aortic injury (BTAI) has led to inquiries into use of stent grafts at other anatomic sites
Use of resuscitative endovascular balloon occlusion of the aorta (REBOA) may be an important adjunct in the control of life-threatening hemorrhage; various physiologic parameters have been shown to improve with REBOA
Minimally invasive techniques for hemorrhage control: intra-abdominal foam and tourniquets

Use of angioembolization for diagnosis and treatment of hemorrhage; improvement in angioembolization devices and technology
Success of thoracic endovascular aortic repair (TEVAR) using endovascular stent grafts to improve morbidity and mortality among patients who survive blunt thoracic aortic injury (BTAI) has led to inquiries into use of stent grafts at other anatomic sites
Use of resuscitative endovascular balloon occlusion of the aorta (REBOA) may be an important adjunct in the control of life-threatening hemorrhage; various physiologic parameters have been shown to improve with REBOA
Minimally invasive techniques for hemorrhage control: intra-abdominal foam and tourniquets

Over the past two decades, considerable progress has been made in the medical management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Recently the field has seen the addition of several new pulmonary vasodilator agents: a soluble guanylate cyclase stimulator (riociguat), a new endothelin receptor antagonist (macitentan) and two new oral prostanoid agents (treprostinil and selexipag).
Initial combination therapy for the treatment of pulmonary arterial hypertension has heralded a new era in the treatment of PAH. Patients receiving initial combination therapy with a phosphodiesterase inhibitor, tadalafil and an endothelin receptor antagonist, ambrisentan demonstrated improved progression-free survival compared with monotherapy with either tadalafil or ambrisentan.
For patients with inoperable or persistent chronic thromboembolic pulmonary hypertension, riociguat has emerged as an attractive alternative.

Evidence that the 9-valent HPV vaccine covers approximately 20% more high-risk infections
Enhanced understanding of the benefits of cervical cancer screening
Interim evidence suggests primary HPV testing is an option for women starting at age 25 years

Evidence that the 9-valent HPV vaccine covers approximately 20% more high-risk infections
Enhanced understanding of the benefits of cervical cancer screening
Interim evidence suggests primary HPV testing is an option for women starting at age 25 years

Evidence that the 9-valent HPV vaccine covers approximately 20% more high-risk infections
Enhanced understanding of the benefits of cervical cancer screening
Interim evidence suggests primary HPV testing is an option for women starting at age 25 years

The updated AJCC TNGM Staging classification for soft tissue sarcomas.
The most recent edition of the WHO Classification of Tumours of the Soft Tissue and Bone lists over 120 different histologic subtypes of soft tissue lesions… Based on data from a randomized trial coordinated by the European Organisation for Research and Treatment of Cancer (EORTC) and on retrospective studies demonstrating an association between treatment with neoadjuvant chemotherapy and improved disease-specific survival in patients with large, high-grade, extremity lesions, neoadjuvant chemotherapy is considered for patients with high-grade tumors that are larger than 10 cm.
In most instances, neither computed tomography nor magnetic resonance imaging can define the histologic subtype, although they can be highly suggestive; for example, myxofibrosarcoma often has tail-like projections spreading along fascial planes and enhancing after administration of contrast.

Cardiovascular Medicine